Table 2.
Clinical follow-up score
| None | CR | Significantly |
Moderately |
Slightly |
Equal | Slightly |
Moderately |
Significantly |
|
|---|---|---|---|---|---|---|---|---|---|
| Improved | Worse | ||||||||
| General | +3 | +2 | +1 | 0 | −1 | −2 | −3 | ||
| Skin | +3 | +2 | +1 | 0 | −1 | −2 | −3 | ||
| Oral mucosa | +3 | +2 | +1 | 0 | −1 | −2 | −3 | ||
| GI tract | +3 | +2 | +1 | 0 | −1 | −2 | −3 | ||
| Eyes SCORE (sum) | +3 | +2 | +1 | 0 | −1 | −2 | −3 | ||
To monitor and quantify the clinical course of GvHD symptoms, the general condition as well as the status of the skin, mucosa, eyes and the GI-Tract were documented. Symptoms were scored, as compared to the previous visit, by +1 to +3 points for improvement of symptoms, while worsening of disease activity was scored by −1 to −3. Scores were cumulatively added up throughout the entire follow-up period. CR, complete remission; GI, gastrointestinal.